Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Share-based Compensation (2016 - 2025)

Zevra Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 6.62% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $12.6 million, down 15.24%, while the annual FY2025 figure was $12.6 million, 15.24% down from the prior year.
  • Share-based Compensation reached $4.3 million in Q4 2025 per ZVRA's latest filing, up from $2.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.1 million in Q3 2024 to a low of $318000.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $2.0 million, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 374.84% in 2022, then plummeted 54.85% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $823000.0 in 2021, then rose by 16.04% to $955000.0 in 2022, then surged by 200.84% to $2.9 million in 2023, then soared by 39.85% to $4.0 million in 2024, then increased by 6.62% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Share-based Compensation are $4.3 million (Q4 2025), $2.8 million (Q3 2025), and $2.5 million (Q2 2025).